Supplementary Figure 3 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer
openalex(2023)
摘要
Supplementary Figure 3. A. No significant differences in stromal TILs were found between pre- and post-treatment samples in all arms. In Arm D TILs were increased post-treatment in most of the samples (5 out of 7). Figures B and C show representative images of TILs in pre- and post-treatment samples respectively from one patient in Arm D, measured by QuPath v0.3.0. Figures show tissues before (left) and after (right) QuPath annotations. Color legend; red, tumor cells; purple, lymphocytes; green, fibroblasts; yellow, other; Cisplatin-Olaparib, C-O; Olaparib, O; Durvalumab-Olaparib, D-O
更多查看译文
关键词
neck cancer,olaparib,cisplatin,durvalumab,operable head
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要